Retatrutide
Retatrutide is a triple GLP-1/GIP/glucagon agonist, still in Phase 3 trials (TRIUMPH program). Investigational — not FDA-approved. It is not available by prescription or compounded, and Retawiz does not sell, source, or help you obtain it.
Not available — not sold, not sourced here
Retatrutide cannot legally be prescribed or compounded in the U.S. today. Retawiz does not sell, source, rank vendors for, or link to any place to obtain retatrutide — and never will, before or after approval outside a licensed-provider model.
Read: Is retatrutide legal? →TRIUMPH trial timeline (estimated)
Lilly has not announced an official approval date. These are third-party estimates and can shift.
| Milestone | Estimated timing | Status |
|---|---|---|
| Phase 3 trials (TRIUMPH program) | 2023–2026 | Ongoing / reporting |
| NDA submission to FDA | Late 2026 – early 2027 | Anticipated |
| FDA review (~10–12 months) | 2027 | Pending filing |
| FDA approval decision | Late 2027 (estimated) | Estimated |
| Commercial launch | 2028 (estimated) | Estimated |
Side effects
Common
Nausea, Diarrhea, Vomiting, Constipation, Decreased appetite
Serious (less common)
Pancreatitis (class effect, monitored in trials), Gallbladder disease (class effect, monitored in trials)
When to contact a clinician
- Retatrutide is investigational — trial-reported side effects only, not a full label safety profile
- Severe, persistent abdominal pain — seek care immediately
Source: Lilly trial disclosures